Q: I’m looking at your recent comments that SIS still has good long term prospects in spite of their new issue to pay off debts. Having looked at their 7% drop I was thinking about adding to my position, but I see it is still selling at 25x earnings!
Do you think this price is justified? And would you expect there to be more price volatility up or down in the near future, ie meriting holding on for more price correction?
Q: Hi 5i,
On June 29 you were asked for the best metrics to evaluate a royalty company like DHT.UN and your answer was:
We think the best metrics are distribution as a percentage of free cash flow (targeted between 30 and 35% as per management), new royalty transactions or pipeline, and EBITDA and FCF multiples.
Could you please supply the current numbers and information to fill in those metrics for DHT.UN, along with your commentary about what they lead you to conclude about the current health and future prospects of DHT.UN.
Q: Can you compare INMD and ISRG in terms of:
- Risk, Potential Upside, Management, Moat, and Overall?
If you can score them between 1-5, that'd be helpful as it helps me understand how they compare relative to each other.
Q: Hi ILMN has had poor relative strength lately. Do you still see it as a good strong growth company, or had the thesis changed? I'm happy to consolidate into ISRG or INMD if they look to be superior.
Q: WELL is trading at 4.25 today. What would be a fair price on evaluation and which one would be the preferred metric for a ballpark price that I can use for this and others.
Q: With respect to assessing Moderna's fair value as a company, what is the value of their patents and pipeline of future messenger-RNA based treatments/vaccines for heart disease, cancer, etc?
Has the market factored this into the share price?
Q: Each of MPW and NWH.un seem to be having issues despite their ostensibly strong medical business strategies. Can you recommend medical properties ETF/Landlords who are doing better vis-a-vis growth/dividend?